SCHEMBL19686207

SCHEMBL19686207

Cc1cc(C)c(OCC(N)c2ccccc2)cn1

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 12/20 0.63
TACR1 P25103 6/20 0.46
AKT1 P31749 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686104 0.79 SCN4A (0.68) SCN4ATACR1AKT1
SCHEMBL21325170 0.79 SCN4A (0.74) SCN4ATACR1
SCHEMBL2395448 0.78 SCN4A (1.00) SCN4ATACR1
SCHEMBL6275527 0.78 SCN4A (1.00) SCN4ATACR1
SCHEMBL19686117 0.77 SCN4A (0.63) SCN4ATACR1AKT1
SCHEMBL19686206 0.76 SCN4A (0.62) SCN4ATACR1AKT1
SCHEMBL19686205 0.75 SCN4A (0.60) SCN4ATACR1AKT1
SCHEMBL21325182 0.74 SCN4A (0.64) SCN4ATACR1AKT1
SCHEMBL19668641 0.74 SCN4A (0.79) SCN4ATACR1
SCHEMBL19686573 0.73 SCN4A (0.67) SCN4ATACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2019-09-05 US disclosed
WO-2017210371-A2 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS SCN1B, CACNA1E, SCN2B SCN4A 48/4885TACR1 174/4885AKT1 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.